Benzinga··PrnewswirePsychedelic Drug Developers Entering Final Testing Phase for Mental Health Treatments
Five biotech firms advance psychedelic therapies to Phase 3 trials for depression and anxiety, with multiple readouts expected in 2026, marking progress toward regulatory approval.
ATAIDFTXGHRSLBRXpsychedelic biotechnologyPhase 3 trials